PRVB - Provention Bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
10.21
-0.24 (-2.30%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close10.45
Open10.50
Bid10.20 x 1100
Ask10.29 x 900
Day's Range10.06 - 10.57
52 Week Range1.52 - 22.82
Volume304,714
Avg. Volume982,979
Market Cap453.738M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.94
Earnings DateAug 6, 2019 - Aug 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.00
Trade prices are not sourced from all markets
  • PR Newswire

    Provention Bio Announces Key Addition to its Leadership Team

    - Appoints Dr. Sherron Kell as SVP of Clinical Development and Program Lead for PRV-031 (Teplizumab) - OLDWICK, N.J. , Aug. 20, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage ...

  • GuruFocus.com

    Provention Bio Inc (PRVB) President and CEO Ashleigh Palmer Bought $96,990 of Shares

    President and CEO of Provention Bio Inc (30-Year Financial, Insider Trades) Ashleigh Palmer (insider trades) bought 10,600 shares of PRVB on 08/08/2019 at an average price of $9.15 a share. Continue reading...

  • PR Newswire

    Provention Bio Initiates Phase 1b/2a PREVAIL Clinical Trial Evaluating PRV-3279 in Lupus

    -Bispecific Diabody Designed to Intercept B-Cell Mediated Autoimmune Diseases- OLDWICK, N.J. , Aug. 8, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company ...

  • PR Newswire

    Provention Bio Reports Second Quarter 2019 Financial Results

    PRV-031 Granted Breakthrough Therapy Designation for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals Results from "At-Risk" Study Published in The New England Journal ...

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For August 5, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Allakos (NASDAQ: ALLK ) shares were up 112.6% ...

  • PR Newswire

    Provention Bio Announces Breakthrough Therapy Designation for Teplizumab (PRV-031) for the Prevention or Delay of Clinical Type 1 Diabetes in At-Risk Individuals

    OLDWICK, N.J., Aug. 5, 2019 /PRNewswire/ -- Provention Bio, Inc. (PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to teplizumab (PRV-031) for the prevention or delay of clinical type 1 diabetes (T1D) in individuals at-risk of developing the disease.

  • 5 Best Biotech Stocks of 2019 So Far
    Motley Fool

    5 Best Biotech Stocks of 2019 So Far

    These biotech stocks have at least quadrupled in just over six months this year.

  • PR Newswire

    ActoBio Therapeutics™ Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of Type 1 Diabetes

    GHENT, Belgium, July 1, 2019 /PRNewswire/ -- ActoBio Therapeutics, Inc., a wholly owned subsidiary of Intrexon Corporation (XON) and innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents, has announced that it will progress to the next stage of the Phase Ib/IIa clinical trial for investigational drug AG019 for the treatment of early-onset type 1 diabetes (T1D). This follows a scheduled review by the independent Data and Safety Monitoring Board, which supported moving forward with the study.

  • Benzinga

    Why Consistent Trading Doesn't Always Lead To Consistent Results

    The loss was particularly hard because I was already up $8,000 on the stock, Provention Bio Inc. (NASDAQ: PRVB), before getting stopped out twice in a row, wiping out that profit and putting me in the hold $10,000. When I first saw the stock as a leading gapper on my premarket scanner, there were plenty of factors that might have turned me off from trading PRVB.

  • Benzinga

    Provention Bio Cancels Secondary Offering, Shares Rally

    Provention Bio, Inc. (NASDAQ: PRVB ) has canceled the public offering of common stock previously announced June 10 due to market conditions. Provention Bio had filed a registration statement on form S-1 ...

  • MarketWatch

    Provention Bio's stock surges after calling off public stock offering

    Shares of Provention Bio Inc. surged 4.5% in premarket trade Thursday, after the biopharmaceutical company said it has terminated its planned public stock offering, citing current market conditions. The stock had more than tripled (up 217%) on Monday, after the company reported positive results from a study of its diabetes treatment. The stock then fell 13% on Tuesday, and 1.7% on Wednesday, after Provention looked to take advantage of the rally by proposing a public offering of 5.5 million common shares, which represented about 14.7% of the shares outstanding. On Thursday, the company said it decided not to sell shares after determining that "current market conditions are not conducive for an offering on terms that would be in the best interests of the company's shareholders." The stock has run up nearly 7-fold (up 569.5%) year to date through Wednesday, while the iShares Nasdaq Biotechnology ETF has gained 7.2% and the S&P 500 has advanced 14.9%.

  • PR Newswire

    Provention Bio Announces Termination of Public Offering of Common Stock

    OLDWICK, N.J., June 13, 2019 /PRNewswire/ -- Provention Bio, Inc. (PRVB) announced today that it has terminated the public offering of common stock previously announced on June 10, 2019. The termination results from an assessment by the Company's management that current market conditions are not conducive for an offering on terms that would be in the best interests of the Company's shareholders. The Company intends to withdraw its registration statement on Form S-1 related to the offering and filed with the US Securities and Exchange Commission.

  • TheStreet.com

    2 Small Biotechs With Sagging Shares but Promising Prospects

    As discussed in my column on Monday, small biotechs that need to raise money over the next 12 months as they ramp up sales on recently approved products have been particularly hit hard. Developmental concerns with no approved products are doing much better provided they have adequate cash runways. Data support what should be a successful New Drug Application (NDA) in the near future, but the information wasn't as overwhelming positive as some investors evidently hoped for as MacroGenics shares saw some profit taking in the days after the event.

  • Company News For Jun 11, 2019
    Zacks

    Company News For Jun 11, 2019

    Companies in the news are: CRM, DATA, UBER, UTX, RTN and PRVB

  • Benzinga

    The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 10) Abbott Laboratories (NYSE: ABT ) BIO-TECHNE Corp (NASDAQ: ...

  • PR Newswire

    Provention Bio Announces Proposed Public Offering of Common Stock

    OLDWICK, N.J., June 10, 2019 /PRNewswire/ -- Provention Bio, Inc. (PRVB) announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a registered underwritten public offering of 5,500,000 shares of its common stock. In addition, Provention Bio intends to grant the underwriters a 30-day option to purchase up to an additional 825,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

  • Provention Bio News: Why PRVB Stock Is Skyrocketing Today
    InvestorPlace

    Provention Bio News: Why PRVB Stock Is Skyrocketing Today

    Provention Bio news about one of its drugs has PRVB stock heading higher on Monday.Source: Shutterstock Provention Bio (NASDAQ:PRVB) says that a study of its PRV-031 drug found that it is effective at delaying patients from developing type 1 diabetes. The results from the study show that the treatment is able to delay development of type 1 diabetes by two years.The Provention Bio news notes that the study included 76 individuals ranging from 8 years old to 49 year old. The drug was found to be effective at delaying the development of type 1 diabetes in both children and adults.InvestorPlace - Stock Market News, Stock Advice & Trading TipsWhat may be most amazing about the study is how little it takes to reach these results. The Provention Bio news release points out that it only took one 14-day treatment of the drug to delaying the development of type 1 diabetes in patients.It's also worth mentioning that 60% of patients in the study that were treated with PRV-031 didn't develop type 1 diabetes, despite being at risk to do so. This also marks the first time that an immune modulator has been successful in delaying the disease. * 7 Stocks to Buy As They Hit 52-Week Lows Ashleigh Palmer, CEO of Provention Bio, has this to say about the results."Based on these results, we are evaluating a regulatory path forward for PRV-031 in at-risk individuals. We are also assessing PRV-031 in newly-diagnosed T1D patients in our Phase 3 PROTECT study, which commenced in April. Our broader goal for PRV-031 is to address the continuum of T1D and provide therapeutic options for this life-impacting and life-threatening autoimmune disease that, until now, has seen no disease-modifying innovation since the development of insulin a century ago.PRVB stock was up 309% as of Monday afternoon. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Buy As They Hit 52-Week Lows * 4 Antitrust Tech Stocks to Keep an Eye On * 5 Gold and Silver Stocks Touching Intraday Highs As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Provention Bio News: Why PRVB Stock Is Skyrocketing Today appeared first on InvestorPlace.

  • PR Newswire

    A Single Course of Provention's PRV-031 (Teplizumab) Delays Type 1 Diabetes Onset in High-Risk Individuals by at Least Two Years

    OLDWICK, N.J., June 9, 2019 /PRNewswire/ -- Provention Bio, Inc. (PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that results from the National Institutes of Health (NIH)-sponsored "At-Risk" Study were published on-line in The New England Journal of Medicine and presented at the Scientific Sessions of the 79th Annual American Diabetes Association (ADA) meeting.  The "At-Risk" Study was sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with additional support from JDRF.

  • Could The Provention Bio, Inc. (NASDAQ:PRVB) Ownership Structure Tell Us Something Useful?
    Simply Wall St.

    Could The Provention Bio, Inc. (NASDAQ:PRVB) Ownership Structure Tell Us Something Useful?

    Every investor in Provention Bio, Inc. (NASDAQ:PRVB) should be aware of the most powerful shareholder groups. Insiders...

  • Benzinga

    The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 8) Alcon AG (NYSE: ALC ) BioSig Technologies Inc (NASDAQ: ...

  • PR Newswire

    Provention Bio Reports First Quarter 2019 Financial Results

    PROTECT Pivotal Phase 3 Clinical Study Initiated in Patients with Recent Onset Type 1 Diabetes Top line Data Results for PRINCE and At-Risk Clinical Trials Expected in 2019 OLDWICK, N.J. , May 8, 2019 ...

  • PR Newswire

    Provention Bio Announces Top-Line Results from its Phase 1b PULSE Clinical Trial of PRV-300 in Patients with Moderate-to-Severe Ulcerative Colitis

    OLDWICK, N.J. , May 8, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced ...

  • PR Newswire

    Provention Bio Completes Enrollment of Phase 2a PRINCE Clinical Trial with PRV-6527 in Patients with Moderate to Severe Crohn's Disease

    OLDWICK, N.J., April 24, 2019 /PRNewswire/ -- Provention Bio, Inc. (PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has completed the enrollment in its Phase 2a PRINCE (PRovention Investigation in Crohn's DiseasE) clinical trial evaluating PRV-6527 in patients with moderate-to-severe Crohn's disease. "The on-schedule completion of enrollment in the PRINCE study for PRV-6527 is yet another significant executional achievement and operational milestone in our mission to develop therapeutics that intercept or prevent immune-mediated diseases," said Ashleigh Palmer, CEO of Provention Bio.

  • Provention Bio, Inc. (PRVB) Shares March Higher, Can It Continue?
    Zacks

    Provention Bio, Inc. (PRVB) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Provention Bio, Inc. (PRVB).

  • PR Newswire

    Provention Bio Initiates Phase 3 PROTECT Clinical Trial with PRV-031 (Teplizumab) in Patients with Recent Onset Type 1 Diabetes

    Pivotal Study to Evaluate Potential of Anti-CD3 Monoclonal Antibody to Intercept Type 1 Diabetes OLDWICK, N.J. , April 9, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical ...